These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
745 related articles for article (PubMed ID: 27179263)
1. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. Depmann M; Eijkemans MJ; Broer SL; Scheffer GJ; van Rooij IA; Laven JS; Broekmans FJ Hum Reprod; 2016 Jul; 31(7):1579-87. PubMed ID: 27179263 [TBL] [Abstract][Full Text] [Related]
2. Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study. Dólleman M; Verschuren WM; Eijkemans MJ; Broekmans FJ; van der Schouw YT Hum Reprod; 2015 Aug; 30(8):1974-81. PubMed ID: 26082477 [TBL] [Abstract][Full Text] [Related]
3. Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. Dólleman M; Depmann M; Eijkemans MJ; Heimensem J; Broer SL; van der Stroom EM; Laven JS; Van Rooij IA; Scheffer GJ; Peeters PH; van der Schouw YT; Lambalk CB; Broekmans FJ Hum Reprod; 2014 Mar; 29(3):584-91. PubMed ID: 24435779 [TBL] [Abstract][Full Text] [Related]
9. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Lie Fong S; Laven JSE; Duhamel A; Dewailly D Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584 [TBL] [Abstract][Full Text] [Related]
10. The association of low ovarian reserve with cardiovascular disease risk: a cross-sectional population-based study. de Kat AC; Verschuren WM; Eijkemans MJ; van der Schouw YT; Broekmans FJ Hum Reprod; 2016 Aug; 31(8):1866-74. PubMed ID: 27496945 [TBL] [Abstract][Full Text] [Related]
11. Genetic variation may modify ovarian reserve in female childhood cancer survivors. van Dorp W; van den Heuvel-Eibrink MM; Stolk L; Pieters R; Uitterlinden AG; Visser JA; Laven JS Hum Reprod; 2013 Apr; 28(4):1069-76. PubMed ID: 23360674 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss. van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706 [TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women. Verdiesen RMG; van der Schouw YT; van Gils CH; Verschuren WMM; Broekmans FJM; Borges MC; Gonçalves Soares AL; Lawlor DA; Eliassen AH; Kraft P; Sandler DP; Harlow SD; Smith JA; Santoro N; Schoemaker MJ; Swerdlow AJ; Murray A; Ruth KS; Onland-Moret NC Hum Reprod; 2022 May; 37(5):1069-1082. PubMed ID: 35274129 [TBL] [Abstract][Full Text] [Related]
14. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility. Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431 [TBL] [Abstract][Full Text] [Related]
15. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM; Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326 [TBL] [Abstract][Full Text] [Related]
16. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study. Koedooder R; Singer M; Schoenmakers S; Savelkoul PHM; Morré SA; de Jonge JD; Poort L; Cuypers WJSS; Beckers NGM; Broekmans FJM; Cohlen BJ; den Hartog JE; Fleischer K; Lambalk CB; Smeenk JMJS; Budding AE; Laven JSE Hum Reprod; 2019 Jun; 34(6):1042-1054. PubMed ID: 31119299 [TBL] [Abstract][Full Text] [Related]
18. ESHRE guideline: ovarian stimulation for IVF/ICSI Ovarian Stimulation TEGGO; Bosch E; Broer S; Griesinger G; Grynberg M; Humaidan P; Kolibianakis E; Kunicki M; La Marca A; Lainas G; Le Clef N; Massin N; Mastenbroek S; Polyzos N; Sunkara SK; Timeva T; Töyli M; Urbancsek J; Vermeulen N; Broekmans F Hum Reprod Open; 2020; 2020(2):hoaa009. PubMed ID: 32395637 [TBL] [Abstract][Full Text] [Related]
19. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial. Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ; Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613 [TBL] [Abstract][Full Text] [Related]
20. Can we predict age at natural menopause using ovarian reserve tests or mother's age at menopause? A systematic literature review. Depmann M; Broer SL; van der Schouw YT; Tehrani FR; Eijkemans MJ; Mol BW; Broekmans FJ Menopause; 2016 Feb; 23(2):224-32. PubMed ID: 26372034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]